![Blood Podcast artwork](https://is1-ssl.mzstatic.com/image/thumb/Podcasts113/v4/02/82/f4/0282f4cd-40ab-c4eb-7ebd-ab26ffec617e/mza_15952236382953722746.jpg/100x100bb.jpg)
Role of macrophage NOX2 in alveolar homeostasis, hydroxyurea versus peginterferon alfa-2a in high-risk PV and ET, and the emerging PV treatment landscape
Blood Podcast
English - May 12, 2022 16:30 - 20 minutes - 19.2 MB - ★★★★ - 44 ratingsLife Sciences Science hematology oncology medical medical research Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed
In this week’s episode we’ll discuss an undescribed role for NOX2 in maintaining lung homeostasis through suppression of alveolar macrophage activation. We’ll also cover results of a phase 3 randomized trial that compares the safety and efficacy of hydroxyurea and peginterferon alfa-2a in patients with high-risk polycythemia vera and essential thrombocythemia (or PV and ET, respectively). Finally, we’ll go more in depth on the emerging treatment landscape for PV, and the limits of current clinical trial endpoints.